---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-008192"
form_type: "8-K"
ticker: "TOI"
cik: "0001799191"
company_name: "Oncology Institute, Inc."
filed_at: "2022-04-04T23:59:59+00:00"
generated_at: "2026-06-26T09:52:19.309153+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# The Oncology Institute names Mihir Shah as CFO; Dalgleish departs

## Summary
- Scott Dalgleish ceases as CFO effective April 4, 2022; receives 3-month salary continuation and $47,750 bonus.
- Mihir Shah appointed CFO, effective April 4, 2022; previously CFO at Commonwealth Care Alliance ($2B revenue).
- Shah's annual base salary $405,000, target bonus 40%, and equity award of $453,085 (67% options, 33% RSUs).
- Diona Simoneit, Chief Accounting Officer, appointed principal accounting officer effective April 1, 2022.
- Press release issued April 4, 2022; departure unrelated to financial condition or controls.

## SEC filing metadata
- accession: 0001628280-22-008192
- form_type: 8-K
- ticker: TOI
- cik: 0001799191
- company_name: Oncology Institute, Inc.
- filed_at: 2022-04-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799191/000162828022008192/0001628280-22-008192-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799191/000162828022008192/toi-20220401.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-008192
- JSON: https://secwatch.observer/filing/0001628280-22-008192.json
- Plain text: https://secwatch.observer/filing/0001628280-22-008192.txt

## Key facts
- Executive change
  Mihir Shah was appointed as Chief Financial Officer at Oncology Institute, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: Effective as of April 4, 2022, the Company appointed Mihir Shah, to replace Mr. Dalgleish as the Company’s Chief Financial Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799191/000162828022008192/0001628280-22-008192-index.htm
- Executive change
  Scott Dalgleish departed as Chief Financial Officer at Oncology Institute, Inc..
  - Action: ceased serving as
  - Role: Chief Financial Officer
  source text: Mr. Dalgleish will cease serving as the Company’s Chief Financial Officer effective April 4, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799191/000162828022008192/0001628280-22-008192-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.